Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden
PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)Van Andel Research Institute Grand Rapids, MI 49503
PERFORMING ORGANIZATION REPORT NUMBER
SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) 10. SPONSOR/MONITOR'S ACRONYM(S)
U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012
SPONSOR/MONITOR'S REPORT NUMBER(S)
DISTRIBUTION / AVAILABILITY STATEMENTApproved for Public Release; Distribution Unlimited
SUPPLEMENTARY NOTES
ABSTRACTNeuroblastoma (NB) is the most common solid tumor in children, which accounts for 15% of all pediatric cancer deaths in the US. New therapeutic antibodies to treat NB are urgently needed to improve survival. The purpose of this project is to produce patient-specific therapeutic antibodies to treat neuroblastoma. The goal is to develop new methods and strategies to capture the auto-immune response reaction in neuroblastoma patients using phage display and B cell hybridoma technologies.